Details for Patent: 10,849,919

Which drugs does patent 10,849,919 protect, and when does it expire?

Patent 10,849,919 protects MAVENCLAD and is included in one NDA.

This patent has twenty-three patent family members in fourteen countries.

Summary for Patent: 10,849,919

Title:	Cladribine regimen for treating progressive forms of multiple sclerosis
Abstract:	Specific oral dosings, specific oral dosage forms, and/or specific oral dose regimens including Cladribine can be effective for the treatment of progressive forms of Multiple Sclerosis, especially Primary Progressive Multiple Sclerosis and/or Secondary Progressive Multiple Sclerosis. Methods of treatment can be based on specific oral dosings, specific oral dosage forms, and/or specific oral dose regimens including Cladribine.
Inventor(s):	Fernando Dangond, Matthias Dotzauer
Assignee:	Ares Trading SA
Application Number:	US16/199,119
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 10,849,919
Patent Claim Types: see list of patent claims	Use; Dosage form;

Drugs Protected by US Patent 10,849,919

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Emd Serono Inc	MAVENCLAD	cladribine	TABLET;ORAL	022561-001	Mar 29, 2019	AB	RX	Yes	Yes						TREATING NON-EARLY SPMS BY ADMINISTERING ORAL CLADRIBINE AT A FIXED DOSE PER PATIENT, PER BODY WEIGHT AND PER TREATMENT YEAR, WHICH FIXED DOSE IS 1.75 +/- 0.2 MG/KG, TO BE ADMINISTERED WITHIN MONTHS 1 AND 2 IN EACH OF 2 ADJACENT TREATMENT YEARS

International Family Members for US Patent 10,849,919

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	113906
Australia	2018372007
Australia	2024227421
Brazil	112020010282
Canada	3083328